The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed ...

Eli Lilly and Company’s competing weight-loss drug, Zepbound (tirzepatide), could post over ... They were joined by RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

The Richmond, California-based biotech reckons that azelaprag can amplify the weight loss achieved with tirzepatide and improve ... Medicxi, Logos Capital, Octagon Capital, Piper Heartland ...

The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed, Logos ...

Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Enter GetSimpli Oral Tirzepatide, a revolutionary product that promises to transform your approach to weight loss and metabolic health. Unlike traditional weight loss methods that often involve ...